About the Company
rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $RIGL News
RIGL Apr 2024 3.000 call
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over ...
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
KELOWNA, BC / ACCESSWIRE / March 14, 2024 / (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in ...
Chutes & Ladders—Voyager plucks another Biogen exec for top post
Voyager Therapeutics plucks another Biogen exec, naming Ferguson as new CMO. Pfizer names CSO for anti-infectives research ...
Lexaria Bioscience (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO
Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.
Rigel Pharmaceuticals (RIGL) Is Worth Looking Despite A Loss Of -24.84% From High
Rigel Pharmaceuticals (NASDAQ:RIGL) on Friday, March 08, rose 2.61% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.57. A look at the stock’s price ...
News - Poseida Therapeutics
Shares of San Diego, USA-based biotech Poseida Therapeutics were up almost 98% at $4.80 late morning, after it announced it has entered into a broad strategic collaboration and license agreement with ...
Buy Rating Affirmed for Armata Pharmaceuticals Amid Clinical Progress and Strategic Growth
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Armata Pharmaceuticals (ARMP – Research ...
Sangamo Biosciences Earns Buy Rating on Breakthrough Brain-Targeting Gene Therapy Capsid and Strategic Advancements
TD Cowen analyst Ritu Baral has maintained their bullish stance on SGMO stock, giving a Buy rating yesterday. Ritu Baral has given his Buy ...
Lexaria Bioscience Corp.: Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
KELOWNA, BC / ACCESSWIRE / March 14, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment o ...
Loading the latest forecasts...